ArticleBiochemical genetics2026
Identification of the Mutations Spectrum in the Fumarylacetoacetate Hydrolase Gene in Tyrosinemia Type 1 Patients in Northeastern Iran.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Tyrosinemia type 1 is a rare disease with autosomal recessive inheritance. It occurs as a result of mutations in fumarylacetoacetate hydrolase (FAH), causing the accumulation of succinylacetone (SA) and fumarylacetoacetate metabolites, leading to severe damage to the patient's liver and kidney. The present study aimed to identify FAH mutations in patients with tyrosinemia type 1 from northeastern Iran. This research was a cross-sectional study to determine the spectrum of mutations in 14 patients with tyrosinemia type 1 in northeastern Iran. Blood and urine samples were collected from the patients to measure the plasma levels of amino acids (tyrosine, methionine, and phenylalanine) and the urine levels of SA using high-performance liquid chromatography (HPLC) and gas chromatography-mass spectrometry (GC-MS) techniques, respectively. DNA was extracted from the whole blood samples, and then the FAH gene segment was amplified using the polymerase chain reaction (PCR) technique. The PCR products were subsequently sequenced using the Sanger method. In patients' blood, the mean phenylalanine concentration was 49 ± 15.5 µmol/L (reference: 32-85 µmol/L), and methionine was 23.8 ± 2.5 µmol/L (reference: 12-40 µmol/L). The mean tyrosine concentration was 491 ± 153 µmol/L (reference: 10-145 µmol/L). Urine succinylacetone concentration was 131 ± 3.5 mmol/L, nearly 400 times higher than the reference upper limit (0.3 mmol/L). In this study, a total of 11 variants were identified in the FAH gene; including three new ones (c.618A > G, c.1068A > T, and c.331G > A), and eight previously reported variations (c.82-13G > A, c.1062 + 5G > A, c.1009G > A, c.364 + 1G > A, c.961-15G > A, c.709C > T, c.782C > T, and c.267G > C). This study led to the identification of 11 variants in the FAH gene including three novel variants in the patients with tyrosinemia type 1 in Northeastern Iran. These findings can be applied to study the potential role of these mutations in the disease pathogenesis, as well as their potential use in its diagnosis.
Indexed as
Identifiers
40237876What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.